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Abstract
Background: The cortical cytoskeleton network connects the actin cytoskeleton to various membrane proteins,
influencing cell adhesion, polarity, migration and response to extracellular signals. Previous studies have suggested
changes in the expression of specific components in prostate cancer, especially of 4.1 proteins (encoded by EPB41
genes) which form nodes in this network.
Methods: Expression of EPB41L1, EPB41L2, EPB41L3 (protein: 4.1B), EPB41L4B (EHM2), EPB41L5, EPB49 (dematin), VIL2
(ezrin), and DLG1 (summarized as „cortical cytoskeleton” genes) as well as ERG was measured by quantitative RT-
PCR in a well-characterized set of 45 M0 prostate adenocarcinoma and 13 benign tissues. Hypermethylation of
EPB41L3 and GSTP1 was compared in 93 cancer tissues by methylation-specific PCR. Expression of 4.1B was further
studied by immunohistochemistry.
Results: EPB41L1 and EPB41L3 were significantly downregulated and EPB41L4B was upregulated in cancer tissues.
Low EPB41L1 or high EPB41L4B expression were associated with earlier biochemical recurrence. None of the other
cortical cytoskeleton genes displayed expression changes, in particular EPB49 and VIL2, despite hints from previous
studies. EPB41L3 downregulation was significantly associated with hypermethylation of its promoter and strongly
correlated with GSTP1 hypermethylation. Protein 4.1B was detected most strongly in the basal cells of normal
prostate epithelia. Its expression in carcinoma cells was similar to the weaker one in normal luminal cells. EPB41L3
downregulation and EPB41L4B upregulation were essentially restricted to the 22 cases with ERG overexpression.
Expression changes in EPB41L3 and EPB41L4B closely paralleled those previously observed for the extracellular
matrix genes FBLN1 and SPOCK1, respectively.
Conclusions: Specific changes in the cortical cytoskeleton were observed during prostate cancer progression. They
parallel changes in the expression of extracellular matrix components and all together appear to be associated
with oncogenic ERG overexpression. We hypothesize that these alterations may contribute to the increased
invasivity conferred to prostate cancer cells by ERG deregulation.
Background
The progression of epithelial tumors to invasive carcino-
mas involves changes in cell polarity, adhesion and
motility that permit the detachment of cancer cells from
the epithelial layer, their invasion into adjacent tissue
layers and eventually their spread throughout the body.
These processes require reorganization of the cellular
cytoskeleton and altered expression of proteins that
connect it to the cell membrane as well as remodelling
of the extracellular matrix including changes in the
composition and processing of its constituents.
The 4.1 proteins, encoded by the EPB41 (erythrocyte
protein band 4.1) genes, are components of the cortical
cytoskeleton underlying the cell membrane [1,2]. The
family of 4.1 proteins consists of the eponymous 4.1R
protein first identified in erythrocytes (gene: EPB41),
4.1N (EPB41L1), 4.1G (EPB41L2), 4.1B (EPB41L3)a s
well as the less closely related members NBL4
(EPB41L4A), EHM2 (EPB41L4B)a n dE P B 4 1 L 5
(EPB41L5). They form nodes in the cell cortex
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any medium, provided the original work is properly cited.connecting further components of the cortical cytoskele-
ton like spectrins, actin and transmembrane adhesion
proteins, receptors and transporters with each other. In
this fashion 4.1 proteins contribute to the organization
of cell polarity, adhesion and motility, and affect trans-
port through the membrane and responses to growth
factors.
The 4.1B protein is most strongly expressed in neu-
rons and is enriched in the basal cells of certain epithe-
lia [2,3]. In addition to spectrins and actin, known
binding partners comprise the adhesion molecule CD44
that binds hyaluronic acid in the extracellular matrix [1]
and the candidate tumor suppressor disc large 1/DLG1
[4]. The 4.1B protein is downregulated in several carci-
nomas, including prostate cancer [5], likely by deletion
or promoter hypermethylation of the EPB41L3 gene
promoter [6]. Mouse models of prostate cancer progres-
sion suggest that it acts as a metastasis suppressor [7].
In contrast, EHM2 is conspicuous in tumor cells with
high migratory potential, such as metastatic melanoma
and fibrosarcoma cells [8,9]. In prostate cancer, EHM2
has been reported to be overexpressed [6,10] and to
diminish adhesion of prostate cancer cells to collagen
[10]. The most recently discovered 4.1 family member,
the product of the EPB41L5 gene (also called Limulus),
regulates cell adhesion during development [11], but has
not yet been investigated in the context of human
cancer.
The 4.1 proteins are part of a larger protein family
characterized by FERM domains, of which many have
related functions. For instance, the FERM domain pro-
tein ezrin, encoded by the VIL2 gene, connects CD81 at
the cell membrane to the actin cytoskeleton. Ezrin has
been shown to mediate invasion of prostate cancer cells
[12,13], but whether it is overexpressed in prostate can-
cer is not known. The more distantly related protein
dematin, too, interacts with the actin cytoskeleton and
growth factor receptors. It is encoded by the EPB49
gene on 8p21.1, a region frequently deleted in prostate
cancer. Overexpression of dematin in PC3 prostate can-
cer cells changed their morphology towards a more
epithelial phenotype [14], but no investigations of
EPB49 expression in prostate cancer tissues have been
published.
The fundamental reorganization of the cytoskeleton,
its attachment to the cell membrane and the extracellu-
lar matrix during cancer progression are orchestrated
by transcription factors that activate cellular programs
for cell migration and invasion, which are physiologi-
cally employed during embryogenesis, wound healing
and tissue regeneration [15,16]. In cancer, such tran-
scription factors, like Snail/SNAI1, Slug/SNAI2 and
ZEB1, often become deregulated and promote tumor
progression.
In prostate carcinoma, transcription factors of the ETS
family are prominent candidates for oncogenes driving
this facet of tumor progression. Specific members of
this protein family are activated towards oncogenes by
chromosomal translocations [17] placing a structural
ETS transcription factor gene under the control of an
androgen-responsive promoter, resulting in its deregula-
tion and overexpression. The most common transloca-
tion, found in 30-70% of all cases, creates a fusion gene
placing the androgen-responsive promoter of TMPRSS2
in control of the ERG structural gene encoding an ETS
family transcription factor. This genetic aberration
results in the androgen-driven overexpression of intact
or amino-terminally truncated ERG proteins in prostate
epithelial cells. ERG oncoproteins influence tumor cell
proliferation, but exert a more pronounced effect on
migration and invasion through broad changes in gene
expression [18-20]. In accord with a function in promot-
ing tumor progression, TMPRSS2-ERG translocations
are observed in a significantly lower fraction of high-
grade prostate intraepithelial neoplasias, a non-invasive
precursor stage, than in invasive carcinomas [21].
We have previously reported downregulation of
EPB41L3 encoding protein band 4.1B and upregulation
of EPB41L4B encoding EHM2, respectively, in prostate
cancer [6], in accord with observations by other groups
[7,10]. In the present study, we have investigated the
expression of further members of the family as well as
selected genes encoding related or interacting proteins
such as disc large 1, ezrin and dematin, and the relation
of the changes to activation of oncogenic ERG.
Methods
Tissues
High quality RNA was available from 13 benign prostate
tissues and 45 cancer samples collected from patients
undergoing radical prostatectomy for prostate carcinoma
between 1997 and 2002 in our institution as described
in a prior study [Schulz et al, 2007]. TNM classification
was performed according to the rules of the Interna-
tional Union against Cancer from 2002. Twenty cancers
were staged as pT2, 23 as pT3 and two as pT4. Twenty-
six cancer specimens had a Gleason score of 7, 13 < 7
and 6 > 7. At the time of surgery, no distant metastases
were detectable, but 11 patients had lymph node metas-
tases. The patients’ age ranged from 59 to 74 years. Fol-
low-up data were available for all patients with a
median follow-up time of 98 months. High quality DNA
was available from 93 cancer tissues essentially encom-
passing the 45 specimens used for RNA analysis. Of
these 93 cases, 44 were staged as pT2 and 49 as pT3 or
pT4. Sixteen patients had lymph node metastases, but
no distant metastases were detected. Each 27 carcino-
m a sw e r ea s s i g n e daG l e a s o ns c o r e>7o r< 7a n d3 9a
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mittee of the Heinrich Heine University medical faculty.
DNA and RNA extraction
DNA and RNA were extracted from identical powdered
tissues as described previously [22,23]. High molecular
weight genomic DNA was isolated using the blood and
cell culture DNA kit (Qiagen, Hilden, Germany). Total
RNA was isolated using the RNeasy Mini Kit (Qiagen)
following guanidinium/acid phenol/chloroform extrac-
tion (peqGOLD TriFast, peqLab, Erlangen, Germany).
Quality of DNA and RNA was initially checked by spec-
trophotometry and subsequently by agarose gel or capil-
lary electrophoresis, respectively. Only high quality DNA
and RNA preparations were used in the present study.
Reverse transcription and quantitative RT-PCR
cDNA was prepared using SuperscriptII (Invitrogen,
Karlsruhe, Germany) according to the manufacturer’s
protocol with a mixture of random and oligo-dT pri-
mers. Quantitative real-time RT-PCR was performed on
an ABI 7900 instrument using commercially available
Taqman assays specific for the respective mRNAs
(Applied Biosystems, Weiterstadt, Germany), namely HS
00938024-m1 (DLG1), HS 00385004_m1 (EPB41L1), HS
00154988_m1 (EPB41L2), HS 00202360_m1 (EPB41L3),
HS 00603031_m1 (EPB41L4B), HS 01554437_m1
(EPB41L5), HS 00157387_m1 (EPB49), HS
00267195_m1 (MKI67), HS 0018574_m1 (VIL2). TBP
(HS 00427620_m1) was used as a reference gene
throughout. The assay for ERG was chosen to cover
exons common to all oncogenic transcripts [19]. All
reactions were performed with cDNA corresponding to
10 ng of RNA each in at least duplicates using 40 cycles
of 15 s at 95°C and 60 s at 60°C after an initial 10 min
denaturation at 95°C. Each run was standardized using a
dilution series of cDNA from a strongly expressing cell
line or normal tissue. Experimental variation for each
sample was below 10%.
DNA methylation analysis
DNA was bisulfite-treated using the EZ DNA Methyla-
tion Gold Kit (Zymo Research, Freiburg, Germany),
Methylation-specific PCR for GSTP1 was performed as
described [22] and accordingly for EPB41L3 using the
primer pairs 5′-TTTGTGTATTGTTGTTGAGGA
GTG-3′ and 5′-CACAATCCCCCACTCCAAAAA A
CA-3′ to detect unmethylated sequences or 5′-TTG
CGTATCG TCGTCGTCGAGGACG-3′ and 5′-CGC
AATCCCCCACTCCGAAAAACG-3′ to detect methy-
lated sequences at 61°C and 64°C annealing tempera-
ture, respectively. Bisulfite sequencing of the EPB41L1
promoter was conducted by the method described
previously [22] with the newly designed primers
5′-AGAGGAGATAGGTAGAGAGGA-3′ and 5′-CTAA
ACCC(A/G)AAATTCCCCATATC-3′ at 58°C.
Immunohistochemistry
For immunohistochemistry paraffin sections of tissue
microarrays comprising prostate cancer and correspond-
ing benign prostatic tissue samples were treated with
xylene and ethanol. Sections were rehydrated and endo-
genous peroxidase activity was eliminated by H2O2.
After antigen retrieval using a citrate buffer in a pres-
sure cooker, endogenous biotin was blocked. Slides were
incubated with a mouse monoclonal antibody against
4.1B (Santa Cruz Biotechnology, dilution 1:10) overnight
at 4°C. After a second incubation with a biotin-conju-
gated polyvalent antibody, slides were mixed with an
avidin-biotin-peroxidase reagent (Scy Tek, Logan, USA).
Reaction products were visualized by immersing slides
in diaminobenzidine tetrachloride and finally counter-
stained with haematoxilin. For negative controls, slides
were subjected to the entire immunohistochemical pro-
cedure except for the fact that the primary antibody was
omitted. Under these conditions no staining was
observed.
Statistical methods
All statistical calculations were performed with SPSS
18.0. For comparisons between groups Mann-Whitney
U test was employed, correlations were evaluated by
Spearman’s rho, nominal data were evaluated by chi-
square test and follow-up data by log-rank test.
Results
Expression of EPB41 and related genes in prostate cancer
tissues
Expression of EPB41L1, EPB41L2, EPB41L3, EPB41L4B,
EPB41L5, EPB49, VIL2, and DLG1 (summarized as „cor-
tical cytoskeleton” genes) was measured by quantitative
RT-PCR in a well-characterized set of 45 M0 prostate
adenocarcinoma tissues and 13 benign tissues from can-
cer-carrying prostates. As reported previously [6],
EPB41L3 mRNA was highly significantly (Mann-Whit-
ney p < 0.001) diminished and EPB41L4B increased (p =
0.002) in these cancer tissues. The expression of
EPB41L1 was decreased moderately, but significantly in
cancer tissues (Fig. 1). The expression of the five other
genes remained unchanged on average (Additional file
1, Figure S1).
Within the cancer specimens, none of the genes
showed a significant association of its expression level
with tumor stage (pT2 vs. > pT2), Gleason score (< 7
vs. 7 vs. > 7) or lymph node metastasis. Below median
expression of EPB41L1 was associated with significantly
earlier biochemical recurrence, as was above median
expression of EPB41L4B (Fig. 2). In contrast, decreased
Schulz et al. BMC Cancer 2010, 10:505
http://www.biomedcentral.com/1471-2407/10/505
Page 3 of 9expression of EPB41L3 showed only a tendency towards
earlier tumor relapse (Fig. 2).
Expression of 4.1B protein in normal and cancerous
prostate tissue
Immunohistochemical investigation (Fig. 3) revealed that
in normal prostate glands, 4.1B expression was usually
much stronger in basal cells than in secretory epithelial
cells. Of note, although all glands stained positive, 4.1B
expression was quite variable between individual glands
(Fig. 3A, B). In cancerous glands, 4.1B protein remained
detectable. In most cases staining intensity in tumor
glands was similar to that of corresponding benign
secretory epithelial cells within the same section (Fig.
3C). In some cases, 4.1B expression in carcinoma cells
was decreased as compared to secretory epithelial cells
of normal glands (Fig. 3D), but the opposite tendency
was also observed in a few specimens.
DNA methylation analysis of EPB41L3 and EPB41L1
Decreased expression of EPB41L3 was previously shown
to be associated with methylation of its gene promoter
in prostate cancer cell lines and a smaller series of
Figure 1 Expression of EPB41L1 in prostate cancers. Expression
of EPB41L1 mRNA relative to TBP in prostate carcinoma and benign
tissues. Black circles denote carcinoma specimens with ERG
overexpression. Median values are indicated by horizontal lines.
Figure 2 Relation of EPB41L3 and EPB41L4B expression to prostate cancer recurrence. Kaplan-Meyer analysis of biochemical recurrence in
patients with below (lower line in B and C, upper line in A) or above (upper line in B and C, lower line in A) median expression of EPB41L4B (A),
EPB41L1 (B) and EPB41L3 (C). The respective log rank p-values were 0.017, 0.034, and 0.170.
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its frequency and relationship to clinical parameters, the
previously analyzed series was extended to 93 cancer
specimens that were investigated by MS-PCR as
described (a typical result is shown in Additional File 2,
Figure S2). Of these, 61 (65%) cases displayed EPB41L3
hypermethylation. Hypermethylation was more frequent
in higher stage cases, i.e. detectable in 25/44 (57%) of
pT2 vs. 35/49 (71%) of higher stage specimens and 12/
16 (75%) lymph-node positive vs. 49/78 (63%) lymph-
node negative cancers, but the difference was not statis-
tically significant (c
2 > 0.05). Average expression of
EPB41L3 mRNA was significantly lower in carcinomas
with hypermethylation of the gene than in those without
(1.79 ± 0.50 vs. 1.33 ± 0.61; p = 0.025). In the same tis-
sue series, 71 (76%) carcinomas displayed hypermethyla-
tion of GSTP1. Hypermethylation of EPB41L3 was
significantly (p = 0.002) more frequent in tumors with
GSTP1 hypermethylation than in those without.
To investigate methylation as a potential cause of
diminished EPB41L1 expression in cancer, 47 CpG sites
around the transcriptional start site (from bp -208 to
+157) were analyzed by bisulfite sequencing in the pros-
tate cancer cell lines PC3 and LNCaP, in two prostate
cancer tissues with lowered expression, one benign
prostate sample and in leucocytes. None of them dis-
played any methylation, whereas an artificially methy-
lated DNA yielded the expected fully methylated
sequence (data not shown).
Relation to changes in expression of other genes
Next, the expression of all cortical cytoskeleton genes in
the cancer tissues was compared to that of MKI67,
encoding the well established marker of cell prolifera-
tion in cancer, Ki67. Expression of EPB41L4B was posi-
tively (Spearman rho = 0.535, p < 0.001) and expression
of EPB41L3 negatively (ς = - 0.411, p < 0.003) correlated
with the proliferation marker.
In various studies, approximately half of all prostate
cancers have been observed to overexpress the ETS
family gene ERG, predominantly as a consequence of
different chromosomal translocations [24]. To cover all
instances of ERG overexpression, we determined the
expression of an mRNA segment common to all normal
and oncogene transcripts by qRT-PCR and defined over-
expression of ERG as a level exceeding twice that of the
maximum of benign tissues. By that definition in the
present series 22 of 45 cancers overexpressed ERG, by
up to two orders of magnitude (Fig. 4A). Across all
cases, ERG expression was significantly different
Figure 3 Immunohistochemical analysis of protein 4.1B expression in prostate cancer and benign prostatic glands.Aa n dB :
Heterogeneous expression of protein 4.1B in benign prostatic glands. Note stronger expression levels in basal cells (arrows) than in secretory
epithelial cells. C-D: Comparison of 4.1B expression levels in tumor glands (TU) and corresponding benign prostatic glands (N): C and D:
equivalent and slightly decreased, respectively, 4.1B expression in cancer cells compared to secretory cells of normal glands. Original
magnifications: A, D, x200; B, x400; C, x100. E: negative control without primary antibody.
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= 0.029).
Subsequently, expression of the cortical cytoskeleton
genes was compared between the groups with elevated
(ERG-high) and close to normal (ERG-low) ERG expres-
sion (marked in black and red, respectively in Figs. 1
and 4). Expression of EPB41L4B was significantly stron-
ger (p = 0.01) and EPB41L3 significantly lower (Mann-
Whitney U p = 0.01) in ERG-high specimens (Fig. 4B,
C). It is evident from the figure that the majority of
ERG-high cancers displayed decreased expression of
EPB41L3 and increased expression of EPB41L4B,
whereas most of the ERG-low carcinomas had expres-
sion levels of the two genes within the range of benign
tissues. In a similar fashion, EPB41L1 expression was on
average lower in ERG-high than ERG-low cancers (Fig.
1), but in this case the difference was not statistically
significant. None of the other cortical cytoskeleton
genes differed significantly with respect to its expression
between ERG-high and ERG-low cancer tissues.
When comparing these results to previous data from
our group, we noted a close correlation (Spearman rho
= 0.807, p < 0.001) between the expression of
EPB41L4B and SPOCK1, the gene encoding the
extracellular matrix protein testican 1. SPOCK1 expres-
sion is upregulated in prostate cancer and associated
with diminished expression of FBLN1 encoding the
basement membrane component fibulin 1 [25]. Accord-
ingly, expression of FBLN1 was correlated inversely with
that of EPB41L4B (rho = - 0.739, p < 0.001), but corre-
lated well positively with that of EPB41L3 (rho = 0.684,
p < 0.001). Moreover, SPOCK1 expression was signifi-
cantly elevated (p = 0.002) in ERG-high cancers and
that of FBLN1 was significantly diminished (p = 0.047).
The expression of other cortical cytoskeleton genes was
not related to either SPOCK1 or FBLN1 expression.
Discussion
Previous studies have concurrently reported changes in
the expression of EPB41L3/4.1B and EPB41L4B/EHM2
in many prostate cancers. The other members of the 4.1
family had not been studied yet in prostate cancer, but
previous investigations have indicated potential func-
tions for the related proteins ezrin and dematin
[12-14,26,27]. Despite these hints, we did not observe
significant changes in ezrin/VIL2 or dematin/EPB49
mRNA expression in prostate cancer compared to
benign tissues. Instead, the present investigation
Figure 4 Expression of ERG and its relation to EPB41L3 and EPB41L4B in prostate cancers.E x p r e s s i o no fERG, EPB41L3 and EPB41L4B
mRNAs relative to TBP in prostate carcinoma and benign tissues. Black circles denote carcinoma specimens with ERG overexpression. Median
values are indicated by horizontal lines.
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EPB41L4B are quite specific among cortical cytoskeleton
genes, with the exception of EPB41L1.O u rf i n d i n g s
therefore call for a detailed investigation of 4.1N expres-
sion and function in prostatic cells in future studies.
Investigation of EPB41L3 methylation in a larger series
of samples confirmed the presumed association between
its downregulation and hypermethylation. EPB41L3
hypermethylation tended to be more frequent in higher
stage tumors and downregulation of gene expression
tended to be associated with earlier recurrence. The two
changes did not correlate significantly with the same
clinical indicators of tumor progression, which may be
due the limited number of samples studied, since the
tendencies were the same. In any case, these findings
concur with the idea from functional studies in mouse
and cell line models that 4.1B may act as a metastasis
suppressor in prostate cancer [7]. Likewise, although we
did not observe significant associations of EPB41L4B
expression with cancer stage or grade, increased mRNA
expression was associated with earlier recurrence, in
accord with the immunohistochemical study of Wang
et al. [10].
Moreover, the extended EPB41L3 methylation analysis
allowed a comparison with the well-studied hypermethy-
lation of GSTP1. Hypermethylation of GSTP1 can be
detected in a significant fraction of HG-PINs [28], but
more consistently after progression towards invasive car-
cinomas. It is thought to occur as part of an „epigenetic
catastrophe” [29] that involves hypermethylation of
further genes, e.g. APC, RARB2 and RASSF1A.I no u r
tissue series, accordingly, cases with hypermethylation of
GSTP1 have a very high likelihood of displaying hyper-
methylation of these genes as well [22]. EPB41L3 hyper-
methylation appears to occur slightly less frequently and
was notably essentially restricted to cases with GSTP1
hypermethylation. A straightforward interpretation of
this finding is that EPB41L3 hypermethylation occurs in
many prostate cancers in conjunction with or following
the hypermethylation of GSTP1.
In the present study, we observed a good correlation
between the presence of EPB41L3 and EPB41L4B
expression changes on one hand and ERG overexpres-
sion on the other hand. Simply stated, carcinoma tissues
without ERG overexpression showed no differences in
expression of the 4.1 genes towards normal tissues (Fig.
4). Our data therefore suggest that the changes in the
expression of the two cortical cytoskeleton genes might
be a consequence of ERG overexpression. This hypoth-
esis fits with the presumed sequence of events during
prostate cancer development. Fusion genes causing ERG
overexpression can be detected in some pre-neoplastic
HG-PINs, but more consistently in invasive carcinomas
[21] supporting a role of ERG in promoting prostate
cancer invasion and progression. As mentioned above,
this transition is also associated with consistent hyper-
methylation of GSTP1, which may coincide with or pre-
cede hypermethylation of EPB41L3.
A relationship between ERG and the cortical cytoske-
leton proteins is also plausible on functional grounds.
Overexpression of ERG is thought to result in increased
proliferation, invasiveness and motility of prostate can-
cer cells [18-20,30], whereas protein 4.1B has been
shown to oppose invasiveness and metastasis of prostate
cancer cells [5,7] and EHM2 to modulate adhesion of
prostate cancer cells [10]. Our data invite the interpreta-
tion that the changes in EPB41 gene expression are part
of a presumed invasion program directed by ERG and
serve to implement the necessary changes in the cortical
cytoskeleton. Whether cortical cytoskeleton genes are
indeed - directly or indirectly - regulated by ERG, must
now be investigated in cell line and animal models.
Along the same line of argument, we have previously
observed changes in the expression of ECM genes
encoding fibulin 1 (FBLN1)a n dt e s t i c a n1( SPOCK1).
The causes of these changes are so far unclear, since we
did not observe altered gene copy numbers in the
majority of cases or obtain evidence for FBLN1 hyper-
methylation [25]. We have now become aware that
upregulation of SPOCK1 parallels that of EPB41L4B and
downregulation of FBLN1 parallels that of EPB41L3.
Accordingly, the changes in the expression of the ECM
genes were also associated with ERG overexpression.
They may therefore represent changes in the composi-
tion of the extracellular matrix brought about as a con-
sequence of ERG oncogenic activation. The observation
that EHM2 influences cell adhesion to basement mem-
brane collagen is intriguing in that respect [10]. Of note,
the strikingly close correlation between EPB41L4B and
SPOCK1 expression in the tissue samples may be
enhanced by their common regulation by androgens
[10,31]. It remains to be determined whether the ECM
genes are indeed ERG targets.
In this study, we also report the first immunohistochem-
ical investigation of 4.1B protein in prostatic tissues. Not
unexpectedly [2,3], we observed the most prominent
expression in the basal cells of the prostatic glands, while
luminal cells contained less protein. Loss of the basal cell
population is a well-established characteristic of prostate
cancers. The downregulation of EPB41L3 expression may
therefore largely reflect the loss of basal cells during pros-
tate cancer development. Basal cells in the prostate epithe-
lium express GSTP1, in contrast to luminal cells [32].
Accordingly, loss of expression and hypermethylation of
GSTP1 may be related to the loss of the basal cell com-
partment [33]. Consequently, it is tempting to speculate
that the hypermethylation of EPB41L3 in prostate cancer,
too, might be associated with the loss of the basal cell
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expressed also in luminal cells of normal glands and the
expression in cancerous prostatic glands remained overall
comparable to that in the luminal cells, despite the pre-
sence of significant hypermethylation in a majority of the
cases. Indeed, in prostate cancer cell lines with pro-
nounced hypermethylation of the EPB41L3 gene and low
levels of mRNA [6], a small amount of 4.1B protein
remains detectable by blot techniques (Schulz et al.,
unpublished results). The residual expression of the gene
in cancer cells could be due to a low level of transcription
despite hypermethylation of the main promoter or from
an alternative weaker promoter suspected in the gene [34].
Conclusions
Our findings suggest that highly specific changes in the
cortical cytoskeleton occur during the progression of
prostate cancers which parallel changes in the expres-
sion of extracellular matrix genes. Since these changes
are found especially in cases with ERG overexpression,
we hypothesize that they may constitute a part of the
invasion program induced by oncogenic ERG.
Additional material
Additional file 1: Expression of EPB41L2, EPB41L5, EPB49, VIL2, and
DLG1 mRNA in prostate tissues. Box plot representation of expression
of the indicated genes relative to TBP in prostate cancer and benign
tissues as measured by qRT-PCR.
Additional file 2: MS-PCR for EPB41L3 methylation. Photograph of
ethidium-bromide stained agarose gel with PCR products from bisulfite-
treated DNA from numbered tissue samples, leukocytes (Leu) as
unmethylated control, Du145 (Du) as methylated control, or water (W),
using primers specific for the unmethylated (U) or methylated (M)
EPB41L3 promoter. The last lane (MW) contained the size marker.
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